Page last updated: 2024-08-05 11:13:12
thiazolidinone
null
ChEBI ID: 48891
Members (11)
| Member | Definition | Role |
|---|---|---|
| 10058-F4 | A member of the class of thiazolidinones that is 2-sulfanylidene-1,3-thiazolidin-4-one which is substituted at position 5 by a (4-ethylphenyl)methylidene group. It is a cell permeable inhibitor of c-Myc-Max dimerization and exhibits antitumour effects in vivo. It downregulates c-Myc expression and upregulates CDK inhibitors, p21 and p27 resulting in the inhibition of proliferation, induction of apoptosis and cell cycle arrest in G0/G1 phase. | 10058-F4 |
| cgp 52608 | CGP 52608 | |
| ciglitazone | An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist. | ciglitazone |
| DPI2 | A thiazolidinone that is 2-sulfanylidene-1,3-thiazolidin-4-one substituted by 3-{[3-(morpholin-4-yl)propyl]amino}-3-oxopropyl and 4-ethylbenzylidene groups at positions 3 and 5, respectively. It is a ferroptosis inducer. | DPI2 |
| GSK1059615 | A thiazolidinone that is the 5-{[4-(pyridin-4-yl)quinolin-6-yl]methylene} derivative of 1,3-thiazolidine-2,4-dione. A PI3K inhibitor | GSK1059615 |
| latrunculin a | A bicyclic macrolide natural product consisting of a 16-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica and from the Fiji Islands sponge Cacospongia mycofijiensis. Latrunculin A inhibits actin polymerisation, microfilament organsation and microfilament-mediated processes. | latrunculin A |
| latrunculin b | A macrolide consisting of a 14-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica. | latrunculin B |
| rhodanine | rhodanine | |
| risarestat | risarestat | |
| troglitazone | troglitazone | |
| troglitazone sulfate | [2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl] hydrogen sulfate |
Research
Studies (3,776)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 120 (3.18) | 18.7374 |
| 1990's | 577 (15.28) | 18.2507 |
| 2000's | 2,008 (53.18) | 29.6817 |
| 2010's | 934 (24.74) | 24.3611 |
| 2020's | 137 (3.63) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 172 (4.22%) | 5.53% |
| Reviews | 243 (5.97%) | 6.00% |
| Case Studies | 53 (1.30%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3,604 (88.51%) | 84.16% |